Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of CFTX-1554 in Healthy Subjects
NCT05260658Phase 1Completed
- Sponsor
- Confo Therapeutics
- Start
- Feb 2022
- Primary completion
- Feb 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CFTX-1554 in neuropathic pain (4 arms), sponsored by Confo Therapeutics. Primary endpoint: Number of Participants With Adverse Events. Started Feb 2022; status: completed.
02
Drugs
CFTX-1554
03
Conditions
neuropathic pain
Beyond the preview
Go deeper on NCT05260658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05260658.